WO1997020580A1 - Traitement medicamenteux - Google Patents

Traitement medicamenteux Download PDF

Info

Publication number
WO1997020580A1
WO1997020580A1 PCT/GB1996/003000 GB9603000W WO9720580A1 WO 1997020580 A1 WO1997020580 A1 WO 1997020580A1 GB 9603000 W GB9603000 W GB 9603000W WO 9720580 A1 WO9720580 A1 WO 9720580A1
Authority
WO
WIPO (PCT)
Prior art keywords
substance
molecule
ring
compound
conversion
Prior art date
Application number
PCT/GB1996/003000
Other languages
English (en)
Inventor
Tariq Khan
Original Assignee
Aepact Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aepact Limited filed Critical Aepact Limited
Priority to JP9521082A priority Critical patent/JP2000502071A/ja
Priority to EP96940685A priority patent/EP0865298A1/fr
Publication of WO1997020580A1 publication Critical patent/WO1997020580A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Système thérapeutique comprenant: (a) un composé constitué d'une partie spécifique d'une cellule cible et d'une partie capable de convertir une substance en une autre substance; et (b) une molécule capable d'inhiber sensiblement la conversion de ladite substance, ou un précurseur de ladite molécule. Dans un mode de réalisation particulièrement préféré, ladite autre substance est cytotoxique et ladite substance est sensiblement non cytotoxique, le système comprenant en outre ladite substance. Dans un second mode de réalisation particulièrement préféré, ladite substance, dans son état natif, est capable d'inhiber l'activité d'un agent cytotoxique et ladite autre substance a moins d'activité contre ledit agent cytotoxique, le système comprenant en outre (a) un agent cytotoxique et (b) ladite substance.
PCT/GB1996/003000 1995-12-06 1996-12-06 Traitement medicamenteux WO1997020580A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP9521082A JP2000502071A (ja) 1995-12-06 1996-12-06 薬物療法
EP96940685A EP0865298A1 (fr) 1995-12-06 1996-12-06 Traitement medicamenteux

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9524942.1A GB9524942D0 (en) 1995-12-06 1995-12-06 Drug therapy
GB9524942.1 1995-12-06

Publications (1)

Publication Number Publication Date
WO1997020580A1 true WO1997020580A1 (fr) 1997-06-12

Family

ID=10784998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/003000 WO1997020580A1 (fr) 1995-12-06 1996-12-06 Traitement medicamenteux

Country Status (5)

Country Link
EP (1) EP0865298A1 (fr)
JP (1) JP2000502071A (fr)
CA (1) CA2239203A1 (fr)
GB (1) GB9524942D0 (fr)
WO (1) WO1997020580A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024426A1 (fr) * 1998-10-23 2000-05-04 Intelligene Ltd. Ribozymes utilises en tant que promedicaments
JP2002526457A (ja) * 1998-09-18 2002-08-20 イムノメディクス， インコーポレイテッド 化学療法剤の標的特異的な毒性を増加させるための方法および組成物
US6867231B1 (en) 1997-06-14 2005-03-15 Enzacta R & D Limited Therapeutic systems
WO2011036457A1 (fr) * 2009-09-23 2011-03-31 Mologic Ltd Agent peptidique de clairance
WO2014181085A1 (fr) 2013-05-09 2014-11-13 Kenneth Dawson Bagshawe Thérapie antitumorale

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007378A1 (fr) * 1987-03-09 1988-10-06 Cancer Research Campaign Technology Ltd. Amelioration apportees a des systemes d'administration de medicaments
WO1993013805A1 (fr) * 1992-01-09 1993-07-22 Kenneth Dawson Bagshawe Medicaments cytotoxiques utilises en therapie

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007378A1 (fr) * 1987-03-09 1988-10-06 Cancer Research Campaign Technology Ltd. Amelioration apportees a des systemes d'administration de medicaments
WO1993013805A1 (fr) * 1992-01-09 1993-07-22 Kenneth Dawson Bagshawe Medicaments cytotoxiques utilises en therapie

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAGSHAWE K D: "ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT)", JOURNAL OF CONTROLLED RELEASE, vol. 28, no. 1/03, 1 January 1994 (1994-01-01), pages 187 - 193, XP000435249 *
DOWELL, ROBERT I. ET AL: "New Mustard Prodrugs for Antibody-Directed Enzyme Prodrug Therapy: Alternatives to the Amide Link", J. MED. CHEM. (1996), 39(5), 1100-5 CODEN: JMCMAR;ISSN: 0022-2623, 1996, XP002027294 *
SPRINGER, CAROLINE J. ET AL: "Optimization of Alkylating Agent Prodrugs Derived from Phenol and Aniline Mustards: A New Clinical Candidate Prodrug (ZD2767) for Antibody-Directed Enzyme Prodrug Therapy", J. MED. CHEM. (1995), 38(26), 5051-65 CODEN: JMCMAR;ISSN: 0022-2623, 1995, XP002027293 *
SVENSSON H P ET AL: "MONOCLONAL ANTIBODY-B-LACTAMASE CONJUGATES FOR THE ACTIVATION OF A CEPHALOSPORIN MUSTARD PRODRUG", BIOCONJUGATE CHEMISTRY, vol. 3, no. 2, 1 March 1992 (1992-03-01), pages 176 - 181, XP000262174 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867231B1 (en) 1997-06-14 2005-03-15 Enzacta R & D Limited Therapeutic systems
US7138122B2 (en) 1997-06-14 2006-11-21 Enzacta R & D Limited Therapeutic systems
JP2002526457A (ja) * 1998-09-18 2002-08-20 イムノメディクス， インコーポレイテッド 化学療法剤の標的特異的な毒性を増加させるための方法および組成物
WO2000024426A1 (fr) * 1998-10-23 2000-05-04 Intelligene Ltd. Ribozymes utilises en tant que promedicaments
WO2011036457A1 (fr) * 2009-09-23 2011-03-31 Mologic Ltd Agent peptidique de clairance
CN102665768A (zh) * 2009-09-23 2012-09-12 莫洛迪克有限公司 肽清除剂
US8846861B2 (en) 2009-09-23 2014-09-30 Mologic Ltd Peptide clearing agents
CN102665768B (zh) * 2009-09-23 2015-01-21 莫洛迪克有限公司 肽清除剂
WO2014181085A1 (fr) 2013-05-09 2014-11-13 Kenneth Dawson Bagshawe Thérapie antitumorale

Also Published As

Publication number Publication date
CA2239203A1 (fr) 1997-06-12
JP2000502071A (ja) 2000-02-22
EP0865298A1 (fr) 1998-09-23
GB9524942D0 (en) 1996-02-07

Similar Documents

Publication Publication Date Title
US11278627B2 (en) Antibody-drug conjugates and the use of same in therapy
JP6608467B2 (ja) 生体直交型薬物活性化
US5728868A (en) Prodrugs of protein tyrosine kinase inhibitors
JP3592711B2 (ja) 細胞毒性剤治療
US6511663B1 (en) Tri- and tetra-valent monospecific antigen-binding proteins
JP2739122B2 (ja) ２成分系医薬
EP0560947B1 (fr) Proteines monospecifiques trivalentes de liaison aux antigenes
WO2014081301A1 (fr) Activation de médicament bio-orthogonale
US5716990A (en) Drug delivery systems
AU716920B2 (en) Enediyne compounds
WO1997020580A1 (fr) Traitement medicamenteux
EP0620742A1 (fr) Inactivation de medicaments cytotoxiques
CA2177644A1 (fr) Promedicaments polymeriques pour la beta-lactamase et leur utilisation
Hay et al. Antibody-directed enzyme-prodrug therapy (ADEPT)
MXPA96001871A (en) Polymeric profarmacos for the beta-lactamasa yusos de los mis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA GB JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996940685

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2239203

Country of ref document: CA

Ref country code: CA

Ref document number: 2239203

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 521082

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996940685

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996940685

Country of ref document: EP